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1. INTRODUCTION
In  recent  years,  considerable  attention  has  been  focused  on  the
development of new drug delivery systems. There are a number of reasons
for the intense interest in new systems. First, recognition of the possibility of
repatenting  successful  drugs  by applying  the  concepts  and techniques of
controlled  release  drug  delivery  systems,  coupled  with  the  increasing
expense  in  bringing  new  drug  entities  to  market,  has  encouraged  the
development of new drug delivery systems. Second, new systems are needed
to  deliver  the  novel,  genetically  engineered  pharmaceuticals,  i.e.,  the
proteins and peptides, to their site of action without incurring significant
immunogenicity or biological inactivation. Third, treating enzyme deficient
diseases and cancer therapies can be improved by better targeting. Finally,
therapeutic  efficacy  and  safety  of  drugs,  administered  by  conventional
methods, can be improved by more precise spatial and temporal placement
within the body, thereby reducing both size and number of doses.1
ADVANTAGES OF CONVENTIONAL DOSAGE FORMS:
• This is the oldest and commonest mode of drug administration.
It  is  safer and more  convenient than the other mode of drug
administration.
• This mode of drug administration does not need assistance and
non-invasive in nature.
• As mode of administration is non-invasive in nature, so no need
the competent medical personnel for drug administration.
• Inflammation  and  pain  associated  with  parenteral
administration should be avoided.
• The medicament or the dosage forms  need not to be sterile for
oral administration.
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• As it is non-sterile in nature, so it is cheapest when compared
with other dosage forms.
DISADVANTAGES OF CONVENTIONAL DOSAGE FORMS:
• Action is slower and thus not suitable for emergencies.
• Unpalatable drugs are difficult to administer.
• May cause nausea and vomiting.
• This route of administration cannot be used for uncooperative,
unconscious and vomiting patients.
• Certain  drugs  are  not  absorbed  from  oral  route.  (E.g.
streptomycin)
• Some drugs are inactivated by gastric juice (E.g. penicillin G,
Insulin)  or  in  liver  (E.g.  nitroglycerine,  testosterone  and
lidocaine) cannot be administered by oral route.
1.1 ORAL DRUG DELIVERY 2, 3
           Most conventional oral  drug products, such as tablets and
capsules, are formulated to release the active drug immediately after oral
administration, to obtain rapid and complete systemic drug absorption. Such
immediate-release  products result  in  relatively  rapid  drug absorption and
onset of accompanying pharmacodynamic effects. However, after absorption
of the drug from the dosage form is complete, plasma drug concentrations
decline according to the drug's pharmacokinetic profile. Eventually,   plasma
drug  concentrations  fall  below  the  Minimum  Effective  Plasma
Concentration (MEC), resulting in loss of therapeutic activity. Before this
point is  reached,  another dose is  usually given if  a  sustained therapeutic
effect is desired. An alternative to administering another dose is to use a
dosage form that will provide sustained drug release, and therefore maintain
plasma drug concentrations.
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The term modified-release drug product is used to describe products
that  alter  the  timing and/or the  rate  of  release  of  the  drug  substance.  A
modified-release dosage form is defined "as one for which the drug-release
characteristics  of  time  course  and/or  location  are  chosen  to  accomplish
therapeutic or convenience objectives not offered by conventional dosage
forms such as solutions, ointments, or promptly dissolving dosage forms as
presently recognized". Several types of modified-release drug products are
recognized:
1. Extended-release drug products. A dosage form that allows at least a two
fold reduction in dosage frequency as compared to that drug presented as an
immediate-release  (conventional)  dosage  form.  Examples  of  extended-
release dosage forms include controlled-release, sustained-release and long-
acting drug products.
2.  Delayed-release drug products.  A dosage form that releases a discrete
portion or portions of drug, at a time or at times other than promptly after
administration,  although  one  portion  may  be  released  promptly  after
administration. Enteric-coated dosage forms are the most common delayed-
release products.
3.  Targeted-release drug products. A dosage form that releases drug at or
near the intended physiologic site of action. Targeted-release dosage forms
may have either immediate- or extended-release characteristics.
              Modified-release drug products are designed for different routes of
administration  based  on  the  physiochemical,  pharmacologic  and
pharmacokinetic properties of the drug and on the properties of the materials
used in the dosage form. Several different terms are now defined to describe
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the  available  types  of  modified-release  drug  products  based  on  the  drug
release characteristics of the products.
1.2  ORAL  CONTROLLED  RELEASE  DRUG  DELIVERY
SYSTEMS2,3
            Oral ingestion is traditionally preferred route of drug administration,
providing  a  convenient  method  of  effectively  achieving  both  local  and
systemic effects. In conventional oral drug delivery systems, there is very
little control over release of drug. The effective concentration at the target
site  can  be  achieved  by  intermittent  administration  of  grossly  excessive
doses,  which  in  most  situations,  often  results  in  constantly  changing,
unpredictable  and  often  sub  or  supra  therapeutic  plasma  concentrations
leaving the marked side effects.
             Oral controlled release drug delivery is a system that provides
continuous oral delivery of drugs at predictable and reproducible kinetics for
a  predetermined  period  throughout  the  course  of  GI  transit  and  also  the
system that target the delivery of a drug to a specific region within the GI
tract for either a local or systemic action.
            An ideal oral  drug delivery system should steadily deliver a
measurable  and  reproducible  amount  of  drug  to  the  target  site  over  a
prolonged  period.  Controlled  Release  (CR)  delivery  system  provides  a
uniform concentration or amount of the drug at the absorption site and thus,
after  absorption  allow  maintenance  of  plasma  concentrations  within  a
therapeutic  range,  which  minimizes  side  effects  and  also  reduces  the
frequency of administration.
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           In order to overcome the drawbacks of conventional drug delivery
systems,  several  technical  advancements  have  led  to  the  development  of
controlled  drug  delivery  system  that  could  revolutionize  method  of
medication and provide a number of therapeutic benefits.
1.2.1 Advantages of Controlled Drug Delivery Systems:
• Maintenance of  plasma drug concentration within an optimal
therapeutic range for prolonged duration of treatment.
• More consistent and prolonged therapeutic effect is observed.
• Maximization of efficiency-dose relationship.
• Employ  less  total  drug  than  that  in  combined  conventional
dosage forms.
• Reduction of adverse side effects.
• Minimization of the need for frequent dose intake.
• Improved patient compliance.
• Improves control of condition i.e., reduced fluctuation in drug
level.
• Minimize or eliminate local side effects.
• Minimize drug accumulation with chronic dosing.
• Make use of special effects, e.g. Sustained-release aspirin for
morning relief of arthritis by dosing before bed time.
• Economy i.e. reduction in health care costs. The average cost of
treatment over an extended time period may be less, with lesser
frequency of dosing, enhanced therapeutic benefits and reduced
side effects.
1.2.2 Disadvantages of Controlled Drug Delivery Systems:
• Increased variability among dosage units.
• Poor in vitro – in vivo correlation.
• Toxicity due to dose dumping may occur when more than usual
fraction is being released.
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• Retrieval  of  drug  is  difficult  in  case  of  toxicity,  poisoning  or
hypersensitivity reactions.
• More rapid development of tolerance.
• Need for additional patient education and counseling.
Figure No.1
A  hypothetical  plasma  concentration-time  profile  from  conventional
multiple dosing and single doses of  sustained and controlled delivery
formulations. (MSC = Maximum Safe Concentration, MEC = Minimum
Effective Concentration)
1.3  SELECTION  OF  DRUG  CANDIDATE  FOR  CONTROLLED
RELEASE DOSAGE FORMS4
                             The physico - chemical properties of the drug such as pKa,
partition coefficient, biological half life, molecular weight, dose of the drug
etc., have to be considered before selection.
Characteristics of drugs suitable for formulation as Sustained Release
Products
• Exhibit moderate rates of absorption and excretion.
• Uniform absorption throughout the gastrointestinal tract.
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• Administered in relatively small doses.
• Possess good margin of safety.
• Used for treatment of chronic therapy.
Characteristics  of  drugs  unsuitable  for  formulation  as  Sustained
Release Products
• Not effectively absorbed in the lower intestine (Riboflavin).
• Absorbed and excreted rapidly i.e. short biological half lives, less
than one hour (Penicillin G, Frusemide).
• Long  biological  half  lives  greater  than  12  hours  (Diazepam,
Phenytoin).
• Large doses required, 1gm (Sulphonamides)
• Drugs with low therapeutic index (Phenobarbital, Digoxin).
• Precise dosage titrated to individuals required (anticoagulants)
• No clear advantage for sustained release formulation (griseofulvin)
1.4 FACTORS INFLUENCING THE DESIGN AND PERFORMANCE
OF CONTROLLED RELEASE PRODUCTS4
                        The design of controlled - release delivery system is
subjected to several variables of considerable importance. Among these, the
properties  of  the drug,  the route of  drug delivery,  and the disease being
treated and length of the therapy have major importance.
1. Physicochemical factors
a. Aqueous solubility
b. Partition coefficient
c. Drug stability
d. Protein binding
e. Molecular size and Diffusivity
2. Biological factors
a)  Absorption
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b)  Distribution
c)  Elimination
d)  Biological half life and Duration of action
e)  Side effects  and Margin of safety
f)  Dose size
g) Disease state
1.4.1 PHYSICOCHEMICAL FACTORS4
a. Aqueous solubility: 
                The aqueous solubility of a drug influences its dissolution
rate, which in turn establishes its concentration in solution and hence the
driving force for diffusion across membrane. The choice of mechanism for
oral sustained release systems is limited by aqueous solubility of the drug.
Diffusion systems will be poor choices for slightly soluble drugs since the
driving force for  diffusion; the concentration in aqueous solution will  be
low. Such drugs may be effectively incorporated in matrix system.
Partition coefficient:
Partition coefficient (Ko/w) is defined as the ratio of the fraction
of the drug in an oil phase to that of an adjacent aqueous phase.
                                                              K=C0/Cw
Where,
C0   = Equilibrium concentration of all forms of the drug e.g. ionized
and unionized in an organic phase at equilibrium
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Cw = Equilibrium concentration of all forms in aqueous phase
Accordingly, compounds with a relatively high Ko/w are predominantly
lipid-soluble  and  consequently,  have  very  low  aqueous  solubility.
Furthermore,  these  compounds  can  usually  persist  in  the  body  for  long
periods  as  they  can  localize  in  the  lipid  membranes  of  cells.  (e.g.:
Phenothiazines).  Compounds  with  very  low  Ko/w  will  have  difficulty  in
penetrating  membranes,  resulting  in  poor  bioavailability.  Furthermore,
partitioning effects apply equally to diffusion through polymer membranes.
The  choice  of  diffusion-limiting  membranes  must  largely  depend  on
partitioning characteristics of the drug. Drugs with a partition coefficient that
is  higher  or  lower  than  the  optimum (i.e.,  1000/1)  in  general,  are  poor
candidates for formulation into Controlled Release dosage forms.
b. Drug stability:
                       Orally administered drugs can be subject to both acid base
hydrolysis and enzymatic degradation. For drugs like Propanthline that are
unstable in the stomach, the most appropriate controlling unit would be the
one that releases its contents only in the intestine. The reverse in the case for
drugs like Propanthline that are unstable in the environment of the intestine,
the most appropriate controlling unit in this case would be one that releases
its contents only in the stomach. In general, drugs with significant stability
problems in any particular area of the gastrointestinal tract are less suitable
for formulation into controlled release systems.
c. Protein binding:
                        Many drugs bind to plasma proteins with a significant
influence on the duration of drug action. If  a drug has binding properties
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with  a  particular  protein,  then  the  distribution  of  the  drug  into  the
extravascular space is governed by the equilibrium process of dissociation of
the drug from the protein. The drug-protein complex can serve therefore as a
reservoir in the vascular space for controlled drug release to extravascular
tissues,  but  only  for  those  drugs  that  exhibit  a  high  degree  of  binding.
Extensive binding to plasma proteins will be evidenced by a long half-life of
elimination for the drug and such drugs generally do not require a controlled
release dosage form.
d. Molecular size and Diffusivity:
                        Drugs in most of the sustained release systems must diffuse
through a  rate  controlling membrane  or  matrix.  The ability of  a  drug to
diffuse  through  these  membranes  is  known  as  diffusivity  (diffusion
coefficient). This diffusivity is a function of its molecular size (or molecular
weight) and is related by the equation.
                            Log D = SvlogV +Kv = SmlogM + Km
Where,
D = Diffusivity
M = Molecular weight
V = Molecular volume
Sv, Sm, Kv and Km = Constants in a particular system.
In general the denser the medium, the smaller is the diffusivity.
1.4.2 BIOLOGICAL FACTORS4
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                   The design of sustained release products should be based on a
comprehensive picture  of  drug disposition.  This  would  entail  a  complete
examination  of  the  ADME  characteristics  of  a  drug  following  multiple
dosing.
i. Absorption:
                    The rate, extent and uniformity of absorption of a drug are
important factors when considering it’s formulation into a sustained release
dosage form. To maintain a constant blood or tissue level of drug, it must be
uniformly released from the sustained release system and then uniformly
absorbed.  Since  the  rate-limiting  step  in  drug delivery from a  controlled
release product is its release from a dosage form, a rapid rate of absorption
of drug relative to its release is essential if the system is to be successful. In
case of sustained release dosage form, the rate constant for drug release is
much less than the constant for drug absorption (i.e., Kr  <<<Ka). Assuming
that  the transit  time  of  a  drug through the absorption area  of  the  gastro
intestinal tract is between 9 and 12 hrs, the maximum absorption half-life
should be 3 to 4 hrs. 
                    This corresponds to a minimum absorption rate constant Ka of
0.17 to 0.23 hr-1 necessary for about 80 to 95 % absorption over a 9 to 12 hr
transit time. For a drug with a very rapid rate of absorption (i.e., Ka >> 0.23
hr-1), the above discussion implies that a first order release rate constant Kr <
0.17  hr-1 is  likely to  result  in  unacceptably  poor  bioavailability  in  many
patients. Therefore, slowly absorbed drugs will be difficult to formulate into
controlled release dosage forms.
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ii. Distribution:
                   Two parameters that are used to describe the distribution
characteristics of a drug are its apparent volume of distribution (Vd) and the
ratio of drug concentration in the tissue to that in plasma (T/P ratio) at the
steady state. In general, the bound portion of drug can be considered inactive
and unable to cross membranes. At high binding one sees prolonged drug
action. The apparent volume of distribution of a drug is frequently used to
describe the magnitude of distribution, including binding, within the body.
The total apparent volume of distribution for a drug at steady state can be
calculated from the following equation.
Vdss = [(k12+k21)/k21]Vp
Where,
Vdss is the apparent volume of distribution at steady state.
K12 and K21 are the constants for the distribution of drug from the central to
peripheral  compartment  and  from  peripheral  to  central  compartments
respectively.
Vp is the volume of central compartment.
iii. Elimination:
                          Elimination of a drug involves two aspects i.e., metabolism
and excretion. Metabolism of a drug can either inactivate an active drug or
convert an inactive drug to an active metabolite. Drugs that are significantly
metabolized before absorption, either in the lumen or tissue of the intestine,
can show decreased bioavailability particularly from slowly releasing dosage
forms. Metabolism of a drug will be reflected in the elimination rate constant
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of a drug or by the appearance of a metabolite. It is possible to incorporate
this pharmacokinetic property into the design of controlled release product,
provided that the rate and extent of metabolism are predictable and that the
rate  constant(s)  for  the  process  are  not  too  large.  Undoubtedly,  complex
metabolic patterns would make the design much more difficult, particularly
when biological activity is wholly or partly due to a metabolite, as is the
case of Isosorbide 2,5-dinitrate.
iv. Biological half life and Duration of action:
                       The usual goal of an oral sustained release product is to
maintain therapeutic blood levels over an extended period. The elimination
rate is quantitatively described by the half-life. The biological half-life and
hence duration of action of a drug obviously play a major role in the process
of considering a drug for sustained release. Therapeutic compounds with a
short  half-life  are  excellent  candidates  for  sustained-release  preparations,
since this can reduce dosage frequency.  However,  this is  limited,  in  that
drugs with very short biological half life as it may require excessively large
amounts of drug in each dosage unit to maintain controlled effect.
                                  In general, drugs with half-life shorter than two hours
are poor candidates for sustained release preparations. Drugs with long half-
life, more than 8 hrs, are also generally not used in sustaining forms, since
their effect is already controlled.
v. Side effects and Margin of safety:
                               Theoretically, the incidence of side effects can be
minimized  by  controlling  the  concentration  at  which  the  drug  exists  in
plasma at any given time, and hence controlled release formulations appear
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to offer a solution to this problem. By slowing the rate at which the drugs are
released, the chances of gastrointestinal irritation will be reduced due to a
smaller amount of drug exposed to the gastrointestinal mucosa at the given
time. The most widely used measure of the margin of safety of a drug is its
Therapeutic Index (TI).
TI = TD50/ED50
Where,
TD50 = Median toxic dose
ED50 = Median effective dose
Drugs with very small value of therapeutic index usually are poor candidates
as controlled release products.
vi. Dose Size:
                  For orally administered systems, there is an upper limit to the
bulk size of the dose to be administered. In general a single dose of 0.5 to
1gm is considered maximum for conventional dosage form. This also holds
for controlled release dosage forms.
Vii. Disease State:
                 Sometimes the disease states are considered before the designing
of an oral controlled release dosage form. This can be explained by taking
the  example  of  Aspirin  (for  rheumatic  arthritis)  which  is  not  a  suitable
candidate for sustained release dosage form. Still an aspirin sustained release
dosage from could be advantageous to maintain therapeutic concentrations,
particularly through out the night, thus alleviating morning stiffness.
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1.5 TYPES OF ORAL CONTROLLED RELEASE DRUG DELIVERY
SYSTEMS2, 3, 4
                        A number of techniques are used to achieve controlled release
of  drugs  via  the  oral  cavity.  The  majority  of  the  oral  controlled  release
systems relay on dissolution, diffusion or a combination of both mechanisms
to generate slow release of drug.
A. Dissolution controlled release systems
B. Diffusion controlled release systems
C. Diffusion and dissolution systems
D. Osmotically controlled release systems
E. Gastro retentive drug delivery systems
F. Electrically stimulated release devices
G. Ion-exchange resins
A) DISSOLUTION CONTROLLED RELEASE SYSTEMS5
                   A drug with a slow dissolution rate will sustain release rate of
the drug from the dosage form. Here the rate-limiting step is dissolution.
This being true, sustained release preparation of drugs could be made by
decreasing their rate of dissolution.
Dissolution controlled systems can be made either by
• Varying  concentration  of  rate  controlling  coats  or  polymers
(Matrix Dissolution Systems) or
• By administering the drug as a group of beads that have coating
of different thickness (Encapsulated Dissolution Systems)
Padmavathi College of Pharmacy & Research Institute, Dharmapuri. Page 16
Chapter-1                                                                                             INTRODUCTION
• Matrix Dissolution Systems are prepared by compressing the
tablet with a slowly soluble polymer carrier into tablet form.
Wax matrices are prepared either by congealing or dispersion
the drug - wax mixture in water.
Table No.1
Dissolution controlled release system(matrix)
Commercially available products belonging to this category are given below:
Product Active ingredient Manufacturer
Dimetane Extentabs Brompheniramine
maleate
Robins
Quinidex Extentabs Quinidine sulfate Robins
          Encapsulated Dissolution Systems contain beads that have different
coating thickness, their release will occur in a progressive manner. Those
with the thinnest layer will provide the initial dose and the maintenance of
drug levels at later times will be achieved from those with thicker coating.
This dissolution process at steady state is described by the Noyes-Whitney
equation.
dc = KDA(Cs-C) =DA(Cs-C)
dt                          h
Where,
dc/dt = dissolution rate.
KD = Dissolution rate constant.
D = Diffusion coefficient.
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Cs = Saturation solubility of the solid.
C = Concentration of solute in the bulk solution
Table No.2
Dissolution controlled release system(encapsulated)
Commercially available products belonging to this category are given below:
Product Active ingredient Manufacturer
Diamox Sequels Acetazolamide Lederle
Nicobid Temples Nicotinic acid Rorer
B) DIFFUSION CONTROLLED RELEASE SYSTEMS5
                  In these systems the release rate of drug is determined by its
diffusion through a water insoluble polymer. There are basically two types
of diffusion devices.
RESERVOIR DEVICES:
                 Reservoir devices are characterized by a core of drug, the
reservoir,  surrounded  by  a  polymeric  membrane.  The  nature  of  the
membrane determines the rate of release of drug.
                  The methods used to develop reservoir type devices include
micro-encapsulation of drug particles and coating of tablets containing drug
cores.
Advantages:
• These devices can offer zero-order release of the drug.
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Disadvantages:
• System must be physically removed from implant sites.
• Difficult to deliver high molecular weight compounds.
Table No.3
Diffusion controlled release system (reservior)
Commercially available products belonging to this category are given below:
Product Active ingredient Manufacturer
Nico-400 Nicotinic acid Jones
Nitrospan Nitroglycerin Rorer
MATRIX DEVICES:
                           The three major types of materials used in the preparation
of  matrix  devices  are  insoluble  plastics,  hydrophilic  polymers  and  fatty
compounds. The most common method of preparation is to mix the drug
with the matrix material and then compress the mixture. The drug release
from a porous or granular matrix can be described by
M = (Ds.Ca.{P/T}.[2C0-PCa]t)1/2
Where,
P = Porosity of the matrix
T = Tortuosity
Ca= Solubility of the drug in the release medium
Ds= Diffusion coefficient in the release medium
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    Advantages:
• Can deliver high molecular weight compounds.
Disadvantages:
• Cannot obtain zero order release
• Removal of remaining matrix is necessary for implanted systems
Table No.4
Diffusion controlled release system (matrix)
Commercially available products belonging to this category are given below:
Product Active ingredient Manufacturer
Fero-Gradumet Ferrous sulfate Abbott
Choledyl SA Oxtriphylline Parke-Davis
C) DIFFUSION AND DISSOLUTION CONTROLLED SYSTEMS6
 In these systems the release rate of drug is determined by both
the diffusion and dissolution mechanisms.
D) OSMOTICALLY CONTROLLED RELEASE SYSTEMS3
           The osmotic pump represents a newer concept in extended-
release preparations. Drug delivery is controlled by the use of an osmotically
controlled device that promotes a constant amount of water into the system,
either by dissolving and releasing a constant amount of drug per unit time or
by the use of a "push–pull" system that pushes the drug out at a constant rate
as water flows into an expandable osmotic compartment. Drug is released
via a single laser-drilled hole in the tablet.
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            A representative osmotic oral drug product is the "push–pull"
system called  Gastrointestinal  Therapeutic  System (GITS),  developed by
Alza Corporation for nifedipine (Procardia XL) and other drugs. The system
consists  of  a  semipermeable  membrane  and a  two-layer  core  of  osmotic
ingredient and active drug. As water enters the system, the osmotic pressure
builds up from the inner layer, pushing the drug out through a laser-drilled
orifice in the drug layer.
E) GASTRORETENTIVE DRUG DELIVERY SYSTEMS6
            Dosage forms that can be retained in stomach are called Gastro
retentive  Drug  Delivery  Systems (GRDDS).  GRDDS  can  improve  the
controlled delivery of drugs that have an absorption window by continuously
releasing  the  drug  for  a  prolonged  period  of  time  before  it  reaches  its
absorption site thus ensuring its optimal bioavailability.
           The approaches that  have been pursued to  increase the
retention  of  an  oral  dosage  form  in  the  stomach  include  Bioadhesive
systems, swelling and expanding systems, High density systems and Low
density (Floating) systems.
1. Bioadhesive systems:
                         Bioadhesion is the process whereby synthetic and natural
macromolecules adhere to the biological membranes in the body and remain
there for an extended period of time. If the membrane substrate is mucosal
layer  then  the  process  is  referred  to  as  mucoadhesion.  The  bioadhesives
increase the residence time and contact time at the area of absorption and
provide a high concentration gradient across the membrane.
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2. Swelling and Expanding Systems
                             These systems increase the residence time of the dosage
form in the stomach. Particles greater than 10mm are unable to enter the
duodenum and are retained in the stomach. The swelling systems incorporate
hydrogels  which  are  polymers  that  can  swell  up  to  100 times  their  dry
weight. The hydrogels used must be biodegradable.
3. High density systems
                            In High density systems the bulk density of the dosage
form must exceed that of normal stomach and should be at least 1.40. In
preparing such formulations, drug can be coated on a core with heavy, inert
materials such as barium sulfate and titanium dioxide. The weighed pellet
can then be covered with a diffusion controlled membrane.
4. Low density (Floating) systems
                          Floating Drug Delivery Systems (FDDS) have a bulk
density less than gastric fluids and so remain buoyant in the stomach without
affecting the gastric emptying rate for a prolonged period of time. While the
system is floating on the gastric contents, the drug is released slowly at the
desired rate from the system. After release of drug, the residual system is
emptied from the stomach. This results in an increased GRT and a better
control  of  fluctuations  in  plasma  drug  concentration. These  systems  are
suitable  for  drugs  that  are  poorly  soluble  or  unstable  in  the  intestinal
medium.
Padmavathi College of Pharmacy & Research Institute, Dharmapuri. Page 22
Chapter-1                                                                                             INTRODUCTION
F) ELECTRICALLY STIMULATED RELEASE DEVICES7
 These are monolithic devices prepared by using polyelectrolyte gels
which  swell  when  an  external  electrical  stimulus  is  applied,  causing  a
change in  pH.  The release  could be  modulated,  by the  current,  giving a
pulsatile  release  profile.  Precise  control  over  the  release  of  drug  from
devices implanted in the body, such as quantity, timing, is highly desirable
in order to optimize drug therapy. Electrically-controllable drug release from
polyelectrolyte hydrogels is helpful in achieving these goals.
 The mechanisms of drug release include ejection of the drug from the
gel as the fluid phase synereses out, drug diffusion along a concentration
gradient,   electrophoresis of charged drugs towards an oppositely charged
electrode and liberation of the entrapped drug as the gel complex erodes.
G) ION-EXCHANGE RESINS7
Ion exchange systems use resins composed of water insoluble cross
linked polymers. These polymers contain salt-forming functional groups in
repeating positions on the polymer chain. The drug is bound to the resin and
released by exchanging with appropriately charged ions in contact with the
ion-exchange groups.
Resin+
 -
   Drug--    +     X--                  Resin+
      
-    X--    +    Drug—
Conversely,
Resin---
 
-   Drug+   +     Y+               Resin--
      
-    Y+    +     Drug+
Where,
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X—and Y+ are ions in the GI tract. The free drug then diffuses out of the
resin. The drug-resin complex is prepared either by repeated exposure of the
resin to the drug in a chromatography column or by prolonged contact in
solution.
The rate of drug diffusing out of the resin is controlled by the area of
diffusion,  diffusional  path  length  and  rigidity  of  the  resin,  which  is  a
function of the amount of cross-linking agent used to prepare the resin. An
improvement  in  this  system  is  to  coat  the  ion-exchange  resin  with  a
hydrophobic rate-limiting polymer, such as ethylcellulose or wax. These
systems rely on the polymer coat to govern the rate of drug availability.
Table No.5
A representative listing of ion-exchange resins is given below
Product Active ingredient Manufacturer
Biphetamine capsules Amphetamine,
Dextroamphetamine
Fisons
Ionamin capsules Phenteramine Pennwalt
1.6  ORAL  CONTROLLED  DRUG  RELEASE  POLYMERIC
SYSTEMS8
                                    For many years, the major focus of drug related
research has been the synthesis or discovery of potent drugs with new kinds
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of  biological  activity,  which  this  continues  to  be  an  important  area  of
research, increasing attention is being devoted to the manner in which these
drugs  are  delivered.  One  way  has  been  incorporation  of  drugs  in  solid
polymers. Controlled release polymeric systems are the most promising as
they  increase  efficacy  of  drugs  substance  and  reduced  undesirable  side
effects.  The  number  of  polymers  and the  range  of  formulation  variables
available to control the rates of drugs release from controlled release devices
are broad. Selection among these variables is based upon the desired release
rate and duration, the physical and chemical properties of the drug and the
intended site of administration.
CHARACTERISTICS OF IDEAL POLYMERIC SYSTEM:
An ideal polymer system should possess the following characteristics:
• It should be inert and compatible with the environment.
• It should be non-toxic.
• It should be easily administered.
• It should be easy and inexpensive to fabricate.
• It should have good mechanical strength.
Criteria followed in polymer selection:
Polymer  chosen  as  potential  drug  carrier  must  exhibit  certain
properties, as listed below:
• The polymer must be soluble and easy to synthesize, it  must
have a finite molecular weight and narrow distribution.
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• It  should  provide  drug  attachment  or  release  sites  for  the
possibility of incorporation of drug –polymer linkages.
• The  polymer  should  be  compatible  with  the  biological
environment, i.e. non-toxic, non-antigenic and non-provocative
in any other respect.
• It  should  be  biodegradable  or  to  be  eliminated  from  the
organism after the fulfillment of its function.
Types of polymers9
Polymers have been broadly classified as,
Natural  polymers:  These  include  acids,  proteins,  polysaccharides  and
complexes of proteins and polysaccharides.
Synthetic polymers:  These include polyesters,  polyurethane,  polyamides,
polycarbonates,  polysiloxanes,  polyolefins,  polyvinyl  compounds  and
acrylics.
Polymers can also be classified on the basis of their interaction with
water, into non-biodegradable hydrophobic polymers.
1. Hydro gels.
2. Soluble polymers.
3. Biodegradable polymers.
Non-biodegradable polymers: These are inert in the environment of use,
are eliminated or extracted intact from the site of administration and serve
essentially as a rate-limiting barrier to the transport and release of drug from
the device. Common examples of such materials includes polyethylene vinyl
acetate  (PVA),  polydimethylsiloxane  (PDS),  polyurethane(PEU)  ethyl
cellulose, celluloseacetate, polyethylene, polyvinylchloride.
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Hydro gels: These  swell  but  not  dissolve when brought in  contact  with
water.  They are  inert,  remove  intact  from the  site  of  administration  and
function by forming a rate limiting barrier to the transport and release of
drugs. 
Common  examples  include  ployhydroxyethylmethylacrylate  (p-HEMA),
cross-linked  polyvinyl  alcohol,  cross-linked  polyvinyl  pyrolidone,
polyacrylamide and dextran.
Soluble  polymers: These  are  moderate  molecular  weight  uncross-linked
polymers that dissolve in water. These materials can be used alone or in
combination  with  hydrophobic  polymers  to  provide  devices  that  slowly
erode  over  time.  Common  examples  include  polyethylene  glycol  (PEG),
polyvinylalcohol,  Hydroxypropylmethylcellulose (HPMC) and copolymers
of methacrylic acid.
Biodegradable  polymers: These  slowly  disappear  from  the  site  of
administration.  However,  this  disappearance  occurs  in  response  to  a
chemical reaction such as hydrolysis. Common examples include polylactic
acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL) and several
generic classes such as polyanhydrides and polyorthoesters.10
Padmavathi College of Pharmacy & Research Institute, Dharmapuri. Page 27
Chapter-2                                                                                      LITERATURE REVIEW
LITERATURE REVIEW
Padmavathi College of Pharmacy & Research Institute, Dharmapuri. Page 30 
Chapter-2                                                                                      LITERATURE REVIEW
LITERATURE REVIEW
 Aiman  A,  et.  al.,  (2000), reported  controlled  release  of  Gabapentin  from
matrices using glyceryl benzoate11
 Yagi Naomi, et. Al., (2000),  reported the compatibility of combining sustained
release fine granules of nifedipine (SRN) with 32 kinds of drugs was studied of
SRN and drugs in heat sealed packages (polyethylene laminated glassine paper)
were kept at either 20◦C and 75 % R.H. or 30 ◦C and 92% R.H. for 30 days.12
 Shyamala Baskaran,  et. al., (2002), reported the novel approach to zero order
drug delivery via hydro gel for  diltiazem with  HPMC followed by Higuchi
pattern.  Hydro  gel  matrix  tablets  of  the  drug  were  formulated  using
HPMC,SCMC with aim to attain a zero order release.13
 Pandy, et. al., (2003), reported formulation and release systems of sustained
release of Diltiazem using HPMC at polymer ratio 1:60, using HPMC, ethyl
cellulose  and eudragit  as  a  sustaining  materials  in  various  proportions.  The
hardness showed almost required result in the present study.14
 Hajare,  et.  al.,  (2004), reported  a  design  of  oral  matrix  formulation  using
guargum, NaCMC and HPMC. The data obtained were fitted into the Higuchi
Model. Analysis of ‘n’ values of korsmeyer equation indicated that the drug
release involved the diffusion.15
 Srinath,  et.  al.,  (2004), reported  a  complete  study  on  the  kinetics  and
mechanism of  drug  release  from bilayer  tablets  of  Diltiazem HCL.  Matrix
tablets of the drug were formulated using ethyl cellulose, rosin as matrix.16
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 Almeida S, et. al., (2006), reported comparative study on the bio equivalence
of  two  different  Gabapentin  formulations.  A  randomised,  two  periods,  two
sequence, crossover clinical trial in healthy volunteers.17
 Supeecha Wittayalertpanya, et.  al., (2008), reported Bioequivalence study of
two  different  formulations  of  300  mg  Gabapentin  capsule  in  Thai  healthy
volunteers.18
 Gorden  A  Irving,  et.  al.,  (2008),  reported  tolerability  and  safety  of
gastrorententive  once  daily  Gabapentin  tablets  for  the  treatment  of  post
therapetic neuralgia.19
 Gordi T, et. al., (2008), reported Pharmacokinetics of gabapentin after a single
day  and  at  steady  state  following  the  administration  of  gastric-retentive-
extended-release  and  immediate-release  tablets:  a  randomized,  open-label,
multiple-dose, three-way crossover, exploratory study in healthy subjects20
 Pfizer, (2009), reported bioequivalence study of gabapentin between tablet and
liquid formulation and the food effect study of liquid formulation.21
 David Sandercock, et. al., (2009) reported Gabapentin Extended Release for
the Treatment of Painful Diabetic Peripheral Neuropathy.22
 P  M  Ramdas  Bhandarkar,  et.  al.,  (2009), reported  oxidative  clavage  of
Gabapentin with N2 bromosuccinimide in acid medium.23
 Wallace, et. al., (2010) reported Gabapentin Extended-Release Tablets for the
Treatment of Patients with Post herpetic Neuralgia: A Randomized, Double-
Blind, Placebo-Controlled, Multicenter Study.24
 Johns,  et.  al.,  (2010), reported  hydrophilic  polymer  viscosities  on  gastric
retentive drug delivery systems of Gabapentin sustained release tablets25
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 Swati  jagdale,  et.  al.,  (2010),  reported  pharmaceutical  equivalence  of
Gabapentin tablets with various extra granular binders.26
 Cheng-hung Hsu, et.  al.,  (2010)  reported progressive steps of  polymorphic
transformation  of  Gabapentin  polymorphs  studied  by  Hot  stage  FTIR
microscopy.27 
 Abdollah Yari, et. al.,(2011), reported Voltammetric Determination of Trace
Antiepileptic  Gabapentin  with  a  Silver-Nanoparticle  Modified  Multiwalled
Carbon Nanotube Paste Electrode28 
 Butch  KuKanich,  et,  al.,  (2011), reported  Pharmacokinetics  of  oral
Gabapentin in greyhound dogs.29
 Zhixin Zong, et. al.,  (2011) reported the Stabilizing Effect of Moisture on the
Solid-State Degradation of Gabapentin.30
 Ben Achrai,  et.  al.,  (2011) reported  Solubilization of  Gabapentin into HII
Mesophases.31
 Ahmed N, et. al., (2011) reported preparation and Invitro evaluation of floating
microsphere of Gabapentin.32 
 Argoft  CE,  et.  al.,  (2012), reported  clinical  development  of  a  once  daily
gastrorententive  formulation  of  Gabapentin  tablets  for  the  treatment  of  post
therapetic neuralgia.33
 Yun-Seok  Rhee,  et.  al.,  (2012),  reported Invivo/Invitro  relationship  of
Gabapentin from a sustain release tablet formulation: A pharmacokinetic study
in the Bengle dog.34
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 Swetha,  et.  al.,  (2012), reported  formulation  and  invitro  evaluation  of
gastrorentive dosage form of Gabapentin.35
 Cowels, et, al., (2012),  reported steady state pharmacokinetics of Gabapentin
after administration of a novel gastrorentive Extended release formulation in
postmenopausal women with vasomotor symptoms.36
 Beal B, et.  al.,(2012),  reported Gabapentin for once-daily treatment of post-
herpetic neuralgia.37
 James  Tovera,  et.  al.,  (2012), reported  population  pharmacokinetics  and
pharmacodynamics  of  gabapentin  After  Administration  of  Gabapentin
Enacarbil.38
 Dhanalakshmi P, et. al., (2012), reported solid lipid nanoparticles hydrophyllic
drug of Gabapentin for delivery of drugs to the brain.39 
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3. AIM AND OBJECTIVE
                       In recent years, controlled release formulations have received
considerable attention because of number of advantages that are offered in
the field of pharmaceuticals. One of the applications of this technology is
alteration of drug release profile with optimized effect.
               Gabapentin is an anti-epileptic medication, also called an
anticonvulsant. It affects chemicals and nerves in the body that are involved
in the cause of seizures and some types of pain. It has been proved to be
effective  in  both  experimental  and  clinical  pain  without  causing  serious
cardiovascular or respiratory side effects. The usual oral dosage regimen is
50-100mg every  4-6hrs  with  a  maximum dosage of  400mg per  day.  To
reduce the frequency of administration and to improve patient compliance a
sustained release formulation of Gabapentin is desirable.
The aim of this work is to formulate and develop a novel oral
controlled release tablet dosage form of Gabapentin to provide a steady state
drug release over an extended period of time.
The rationale  behind the mechanism and dynamics  of  electrolytes
induced matrix stiffening and structural changes to the gel are the basis of
controlled drug release.
The scope and objective behind this work is to prepare and evaluate
Gabapentin  tablets  in  order  to  control  the  drug  release  using  different
electrolytes in different concentrations.
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4. PLAN OF WORK
The  following  experimental  protocol  was  therefore  designed  to  all
systematic approach to the study.
1) Drug selection.
2) Selection of excipients.
3) Preformulation study: Compatibility evaluation was carried out   between
drug and polymers in physical observation and by using Infra Red spectrum
study.
4) Formulation of controlled release matrix tablets of using different release
retardant.
5) The following evaluation parameters were studied based on laboratory
experiments.
     i) In-process Evaluation of granules:
1. Angle of repose.
2. Apparent bulk density.
3. Tapped bulk density.
4. Percent compressibility.
5. Hausner Ratio.
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ii) Evaluation of tablets:
i. Hardness.
ii. Friability.
iii. Weight variation.
iv. Content uniformity of active ingredient.
v. In-vitro dissolution study.
vi. Stability study of optimized batch.
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Drug Profile of Gabapentin
Chemical Structure:
Chemical Name : 2-[1-(aminomethyl)cyclohexyl]acetic acid 
Molecular weight : 171.237 g/mol
Molecular formula : C9H17NO2 
Physical properties
Description : White to off white
Form : Crystalline solid
Category : Anticonvulsant, neuropathic pain and hot flashes.
Solubility : Freely soluble in water and acidic and basic solutions.
Storage : Store in the refrigerator
Melting Point : 122 to 167°C.
Pka : 3.7
Stability : 91 days at 4°C, 56 days at 25°C.
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Pharmacokinetics Profile:
Bioavailability :  60% to 27%. (According to Dose increasing)
Biological half life :  5 to 7 hrs.
Plasma  protein
binding :  It is less than 3% bound to human serum proteins.
Excretion :  Urinary excretion. 60% to 88% 
 (unchanged drug and metabolites)
Pharmacodynamics Profile:
Mechanism of Action: 
Gabapentin is structurally related to the neurotransmitter GABA
(gamma-amino  butyric  acid)  but  it  does  not  modify  GABAA  or
GABAB  radioligand  binding,  it  is  not  converted  metabolically  into
GABA or a GABA agonist, and it is not an inhibitor of GABA uptake
or degradation.
Gabapentin was formed by the addition of a cyclohexyl group to
gamma-aminobutyric acid (GABA), which allowed this form of GABA
to cross the blood-brain barrier.
Despite its structural similarity to GABA, Gabapentin does not bind to
GABA receptors in the CNS. Its mechanism of action is unknown, but may
involve enhanced neuronal GABA synthesis.
Pharmaco Kinetics:
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Absorption and Bioavailability: It is rapidly and extensively absorbed (at
least  60  to  76%  of  dose)  when  administered  orally.  To  maximize
bioavailability and reduce the risk of gastrointestinal (GI) upset.
Distribution: Less  than  3%  of  gabapentin  circulates  bound  to  plasma
protein. 
Metabolism: 
            The pharmacokinetic profile of Gabapentin is complicated due
to rapid and extensive first-pass metabolism, which is species and dose-rate
specific. In humans, a number of pathways,  including Cytochrome P-450
isozyme, CYP2D6 and CYP3A4, as well as by conjugation of parent and
metabolites.  Phase  II  hepatic  metabolism renders  the  metabolites  water-
soluble, which are excreted by the kidneys.  Thus,  reduced doses may be
used in renal and hepatic impairment.
Elimination:
       Gabapentin is eliminated from the systemic circulation by renal
excretion as unchanged drug. Gabapentin is not appreciably metabolized in
humans.
Contraindications: 
     Gabapentin controlled release tablets causes serious or fatal side-
effects in a newborn including neonatal withdrawal syndrome, if the mother
uses  the  medication  during  pregnancy  or  labor.  Use  of  Gabapentin  by
nursing mothers is not recommended by the manufacturer because the drug
passes into breast milk.
Dosage and Administration:
Padmavathi College of Pharmacy & Research Institute, Dharmapuri. Page 43
Chapter-5                                                                                                              DRUG PROFILE
            300-600 mg daily.  Maintenance: 1200 mg daily (37-50 kg); 900 mg
daily (26-36 kg).
Precaution:
   Patients should be advised that gabapentin may cause dizziness,
somnolence and other symptoms and signs of CNS depression. Accordingly,
they should be advised neither to drive a car nor to operate other complex
machinery  until  they  have gained  sufficient  experience  on  gabapentin  to
gauge  whether  or  not  it  affects  their  mental  and/or  motor  performance
adversely
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6.1 HYDROXY PROPYLMETHYL CELLULOSE41
1  Synonym : Cellulose, E464, HPMC, methocel.
2  Chemical name : Cellulose, 2-hydroxy propyl methyl ether.
3  Empirical formula : (OCH2CH (OH) CH3)
4  Molecular weight : 1, 00, 00 to 1, 50, 00
5 Structural Formula :
6. Functional category   :  Coating agent, film former, stabilizing agent,
    suspending agent, binding agent
7. Description : Odorless, tasteless, white or creamy white    
   fibrous.
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8. Typical Properties:
1.  Bulk density : 0.341 g/cm
2.  Tapped density : 0.557 g/cm
3.  True density : 1.326 g/cm
4. Melting point : 190 to 200°C
5. PH : 5.5 – 8.0
 9. Solubility : Soluble in cold water, practically insoluble in ethanol, ether.
10. Stability and storage conditions : Its stable material, it’s hygroscopic
after drying. Stored in well-closed container. Protected from light
11. Incompatibilities : Incompatible with some oxidizing agents.
12. Safety:  Nontoxic and nonirritant.
6.2 CALCIUM CARBONATE
1. Molecular Formula: CaCO3.
2. Molecular Weight: 100.09.
3. Functional category:  Buffering agent, Diluent, Therapeutic agent.
4. Description: Occurs  as  an  odorless  and  tasteless,  white  powdered
crystals.
5. Applications:
Padmavathi College of Pharmacy & Research Institute, Dharmapuri. Page 47
Chapter-6                                                                                                EXCIPIENTS   PROFILE
a. Employed as a pharmaceutical excipient.
b. Also used as a base for medicated dental preparations.
c. Used as bulking agent in tablet sugar coating processes.
d. Used as an opacifier in tablet film coating.
e. Used as a food additive.
f. Used as an antacid and calcium supplement.
6 .Typical Properties:
1. Bulk density -- 0.8 g/cm
2. Tapped density – 1.2 g/cm
3. Flow ability—cohesive.
4. Melting point – 825°C.
7.  Solubility:  Soluble  in  ethanol,  water,  insoluble  in  mineral  oil  and
vegetable oil.
8.  Stability  and  storage  conditions:  It’s  stable.  Stored  in  well-closed
container. Protected from light.
9. Safety: Nontoxic and Non- mucosal irritant.
6.3 MAGNESIUM CARBONATE
1. Molecular formula:  MgCO3.
2. Molecular weight:     84.32.
3. Functional category: Diluent, Antacid and Adsorbent.
4. Applications:
a) As an excipient, it is mainly used as directly compressible tablet
diluents.
b) Also used in microsphere formulations.
c) Used to absorb liquids, such as flavours in tableting process.
5. Description: Occurs as light, white colored friable masses or as bulky white
powder.
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6. Typical Properties:
1. Bulk density – 0.56 g/cm
2. Tapped density – 0.783 g/cm
3. Flow ability—Cohesive.
4. Melting point – 350°C.
7. Solubility:  Soluble in water, insoluble in miner oil and vegetable oil.
8. Stability and storage conditions:  It’s stable. Stored in well-closed container.
protected from light.
9. Safety: Nontoxic.
6.4 SODIUM BICARBONATE
1. Molecular formula:  NaHCO3.
2. Molecular weight:     84.01.
3. Functional category: Alkalizing agent and therapeutic agent.
4. Applications:
a)  Employed  as  a  source  of  carbon  dioxide  in  effervescent
tablets and granules.
b) Also used to buffer the drug molecules that are weak acids.
c) Also used as freeze-drying stabilizer.
5. Description: Occurs as an odorless, white crystalline powder.
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6. Typical Properties:
1. Bulk density – 0.869 g/cm
2. Tapped density – 1.369 g/cm
3. Flow ability—Cohesive.
4. Melting point – 270°C.
7. Solubility:  Soluble in water, insoluble in mineral oil and vegetable oil.
8. Stability and storage conditions:  It’s stable. Stored in well-closed container.
Protected from light.
9. Safety: Nontoxic.
6.5 SODIUM CARBONATE
1. Molecular formula:  Na2CO3.
2. Molecular weight:     105.99.
3. Functional category: Therapeutic agent.
4. Applications:
a) Employed as a food additive.
b) As a pharmaceutical excipient.
c) As an antacid.
5. Description: Occurs as white colored solid.
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6. Typical Properties:
1. Bulk density – 2.5 g/cm
2. Flow ability—Cohesive.
3. Melting point –851°C.
7. Solubility:  Soluble in water, insoluble in mineral oil and vegetable oil.
8. Stability and storage conditions:  It’s stable. Stored in well-closed container.
Protected from light.
9. Safety: Non toxic.
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MATERIALS AND METHODS
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Table   No. 6
7.1 MATERIALS
Table No .7
7.2 EQUIPMENTS
S. No Name of the Equipment Manufactured by
1. 8 stage dissolution apparatus
Electro lab,
Ahmedabad.
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S.NO INGREDIENTS MANUFACTURER
1. Gabapentin Shasun Pharmaceuticals Ltd, Pondy.
2.
Methocel 
(HPMC )
Shasun Pharmaceuticals Ltd,. Pondy.
3.
Calcium 
carbonate
Shasun Pharmaceuticals Ltd, Pondy.
4.
Magnesium 
carbonate
Shasun Pharmaceuticals Ltd, Pondy.
5.
Sodium 
carbonate
Shasun Pharmaceuticals Ltd, Pondy.
6.
Sodium 
bicarbonate
Shasun Pharmaceuticals Ltd, Pondy.
7. Talc Shasun Pharmaceuticals Ltd, Pondy.
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2. Tableting machine,(Mini Press-II MT)
Rimek 27 Stations, 
Ahemdabad.
3. U.V/Visible spectrophotometer Agilent, Japan.
4. Analytical balance Adair dutt Instruments
5. Friabilator
VEEGO Instruments 
Corporation, Mumbai.
6. Hardness tester
SQC& Inspection 
Instruments, Mumbai.
7. Tray dryer
Pharmafab 
Industries,Hyd.
8. Tapped density tester Electrolab, Ahemdabad.
9. Mechanical stirrer Remimotor, Mumbai.
7.3 CALIBRATION   CURVE OF GABAPENTIN
1. Preparation of 0.1N HCl
8.5 ml of concentrated hydrochloric acid was diluted up to 1000 ml
with distilled water.
2. Preparation of Phosphate buffer pH 6.8
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Accurately  weighted  quantity  of  6.8  g  of  potassium  dihydrogen
phosphate  and  0.89  gms  of  sodium hydroxide  pellets  were  dissolved  in
distilled water and diluted with distilled water up to 1000 ml.
3. Preparation of standard curve in 0.1 N HCl
Accurately weigh one hundred mg of Gabapentin was taken in 100 ml
volumetric  flask  and  dissolved  in  20  ml  of  methanol.   Then  the  above
solution was further diluted up to 100 ml with 0.1 N HCl.  The resulting
solution of 10 ml was taken and diluted up to 100ml to give a stock solution
of  100  µg/ml  with  0.1NHCl  to  get  drug  concentration
2,4,6,8,10,20,30,40,50  µg/ml.  The  absorbances  of  the  solutions  were
measured against 0.1 N HCl (distilled water) as a blank at 270 nm using
double beam UV visible spectrophotometer.   The plot of  absorbance v/s
concentration (µg/ml) was plotted and data was subjected to weighed linear
regression analysis in Microsoft excel.
Observation:
The standard calibration curve of drug in 0.1 N HCl depicted as Fig.2.
The data of absorbance was shown in Table 8.  The data had correlation
coefficient of 0.9995 and the equation of regressed line depicted as eq.1
Y= 0.006 X + 0.0026, R²= 0.9986.
4. Preparation of standard curve in 6.8 pH buffer
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                   Accurately weigh one hundred mg of Gabapentin was dissolved
in 100 ml volumetric flask and dissolved in 20ml of methanol.  Then the
above solution was further diluted up to 100ml with 6.8phosphate buffer.
The resulting solution of 10ml was taken and diluted up to 100ml to give a
stock  solution  of  100µg/ml  with  6.8phosphate  buffer   to  get  drug
concentration of  2,4 ,6,8 ,10,20, 30, 40, 50µg/ml. The absorbances of the
solutions were measured against 6.8phosphate buffer as a blank at 270nm
using double beam UV visible spectrophotometer.  The plot of absorbance
v/s concentration (µg/ml) was plotted and data was subjected to weighed
linear regression analysis in Microsoft excel®
 Observation
The standard calibration curve of  drug in  phosphate buffer  pH 6.8
depicted as Fig.3. The data of absorbance was shown in Table 9. The data
had  correlation  coefficient  of  0.9993  and  the  equation  of  regressed  line
depicted as eq.3
                                         Y= 0.006 X + 0.0042, R²= 0.9963.
                                                
Table No.8
Calibration curve of Gabapentin in 0.1 N HCl at 270nm.
Sample No Concentration (µg/ml) Absorbance (nm)
1. 0 0
2. 2 0.010
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3. 4 0.015
4. 6 0.029
5. 8 0.048
6. 10 0.057
7. 20 0.113
8. 30 0.187
9. 40 0.257
10. 50 0.295
Figure No.2
Calibration curve of Gabapentin with 0.1N Hcl at 270 nm
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Y=0.006x
R2=0.995
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Table No.9
Calibration curve of Gabapentin with 6.8 phosphate buffer at 270nm.
Sample No Concentration (µg/ml) Absorbance (nm)
1. 0 0
2. 2 0.018
3. 4 0.030
4. 6 0.041
5. 8 0.054
6. 10 0.059
7. 20 0.116
8. 30 0.180
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9. 40 0.246
10. 50 0.307
Figure No.3
Calibration curve of Gabapentin with 6.8 pH buffer at 270nm
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7.4 IDENTIFICATION OF THE DRUG WITH I.R.SPECTRUM
         The identification of drug was done by FT-IR spectroscopy. The
FT-IR spectrum of pure drug Gabapentin is shown in Fig No. 4
Procedure:
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Triturate 1-2mg of the drug substance to be examined with 300-400mg,
unless  otherwise  specified  of  finely  powdered  and  dried  potassium
bromide (or) potassium chloride. These quantities are usually sufficient
to give a disc of 10- 15mm diameter and a spectrum of suitable intensity
I.R spectrophotometers are used for recording spectra in the region of
4000- 650 cm-1
Figure. No.4
Identification   of Gabapentin with I.R. Spectrum
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                                    TABLE NO: 10 
Identification   of Gabapentin with I.R. Spectrum
S.NO Wave number(cm-1) Functional groups
1. 3475 N-H
2. 3450 O-H
3. 2950 C-H
4. 6575 C=O
7.5 DRUG AND EXCIPIENT COMPATABILITY STUDY:
In the drug and excipient compatability study, it  was found that
gabapentin is  having compatibility  with all  the excipients  used in  the
formulation. Active drug blended with individual excipients taken in 1:1
ratio. It was filled in closed vials and placed in stability chambers at 25 ±
2ºC at 55 ± 5 % RH and samples were observed for any physical changes
at the end of 30 days, thus the chosen excipients for the formulations
were found to be compatible with the active pharmaceutical ingredients
also there was no change in the physical appearance of the blend.
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TABLE NO: 11
Compatability studies of Drug with Excipients
S.No Drug withExcipients Initial colour
Storage conditions
25°C/55%RH
At the end 60 days
1. D+HPMC colourless colourless
2. D+MgCO3 colourless colourless
3. D+CaCO3 colourless colourless
4. D+NaHCO3 colourless colourless
5. D+Na2CO3 colourless colourless
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8. PREFORMULATION STUDIES
1. BULK DENSITY:
                       It refers to a measurement to describe packing of particles. Bulk
density issued to determine the amount of drug that occupies the volume in gm/cc.
Pi =m/Vi.
      Where,
m =Mass of the blend.
Vi =Untapped volume.
Procedure:
               Weigh the quantity of API and was transferred into a 100ml measuring
cylinder without tapping during transfer. The volume occupied by the API was
measured. Bulk density was measured by using formula.
2. TAPPED DENSITY:
Procedure:
               Weigh the quantity of API and was taken into a graduate cylinder.
Volume occupied by the API was noted down. Then the cylinder was subjected to
500, 750 and 1250 taps in tap density tester (Electro Lab USP II).According to
USP ,the blend was subjected for 500taps.Percentage volume was calculated and
subjected for additional 750 taps. Percentage variation is calculated.
Pt =m/Vt.
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3. COMPRESSIBILITY INDEX:
                      Weigh the quantity of API and was transferred to 100ml graduated
cylinder and subjected to 500, 750 and 1250 taps in tap density tester (Electro
Lab).The difference between two taps should be less than 2%.The Percentage of
compressibility index calculated using formula.
LIMITS:
S.NO Compressibility index Flow
1 5-12 Free flow
2 12-16 Good flow
3 18-21 Fair
4 23-25 Poor
5 33-38 Very  poor
6 > 40 Extremely poor
4. HAUSNER’S RATIO:
      It is the measurement of frictional resistance of the drug. The ideal range
should be 1.2-1.5.It is determined by the ratio of tapped density and bulk density.
                                     Hausner’s ratio =Vi/Vt.
Where,
Vi =Tapped volume.
Vt =Untapped volume.
LIMITS:
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S.NO Hausner’s Ratio Flow
1 1-1.2 Free flowing.
2 1.2-1.6 Cohesive powder.
5. ANGLE OF REPOSE:
                     Weigh the quantity of API and by using the methods of funnel type
and open ended cylinderical methods, observe the height of the pile and the radius
of the  pile  by placing  the  granules  through it  and  the  angle of  repose  can  be
measured by using formula,
[Tan θ =   h/r]
Where,
h = Height of pile.
r = Radius of the base of pile.
θ = Angle of repose.
Relation between Angle of Repose (a) and Powder flow:
S. No. Angle of Repose Flow
1. <25 Excellent
2. 25-30 Good
3. 30-40 Passable
4. 40 & above Very poor
Table No.12
Preformulation Studies Results
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S.No. PARAMETERS RESULTS
1. Bulk density 0.32 --  0.36 g/cc
2. Tapped density 0.601 -- 0.609 g/cc
3. Compressibility index 13 – 15%
4. Hausner’s ratio 1.12-- 1.16
5. Particle size 26º34´--28º56´
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  9. FORMULATION OF GABAPENTIN TABLETS 
The  key process  in  the  formulation development  of  Gabapentin.  Tablets
including direct compression method to be adopted using different excipients and
before weighing active ingredient.  The dispensing area  maintained temperature
below 25ºC  and humidity below 30 % RH.
Procedure:
Accurately weigh the active (Gabapentin) and all  other ingredients, were
individually passed through sieve no.60 and then all the ingredients were mixed
thoroughly by triturating upto 15 min.The mixed powder was lubricated with talc
and the powder was again mixed thoroughly for  punching to tablets  by Direct
compression method.
All the formulations were prepared according to the tables: 13, 14,15,16,17 the
tablets were prepared as per the procedure given below and aim is to prolong the
release of Gabapentin.
Table No.13
Composition of Gabapentin without electrolytes:
S.No. Ingredients Batch(F)
1. Gabapentin 100mg
2. HPMC 50cps 100mg
3. Talc 3.25mg
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Table No.14
Composition of Gabapentin Tablets using Calcium carbonate:
S.No. Ingredients F1 F2 F3 F4
1. Gabapentin 100mg 100mg 100mg 100mg
2. HPMC50cps 100mg 100mg 100mg 100mg
3. Calcium
carbonate 25mg 50mg 75mg 100mg
4. Talc 3.25mg 3.5mg 3.75mg 4.0mg
Table No.15
Composition of Gabapentin Tablets using Magnesium carbonate:
S.No. Ingredients F5 F6 F7 F8
1. Gabapentin 100mg 100mg 100mg 100mg
2. HPMC50cps 100mg 100mg 100mg 100mg
3. Magnesium
carbonate 25mg 50mg 75mg 100mg
4. Talc 3.25mg 3.5mg 3.75mg 4.0mg
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Table No.16
Composition of Gabapentin Tablets using Sodium bicarbonate:
S.No. Ingredients F9 F10 F11 F12
1. Gabapentin 100mg 100mg 100mg 100mg
2. HPMC50cps 100mg 100mg 100mg 100mg
3. Sodiumbicarbonate 25mg 50mg 75mg 100mg
4. Talc 3.25mg 3.5mg 3.75mg 4.0mg
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Table No.17
Composition of Gabapentin Tablets using Sodium carbonate:
S.No. Ingredients F13 F14 F15 F16
1. Gabapentin 100mg 100mg 100mg 100mg
2. HPMC50cps 100mg 100mg 100mg 100mg
3. Sodium
carbonate 25mg 50mg 75mg 100mg
4. Talc 3.25mg 3.5mg 3.75mg 4.0mg
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10. EVALUATION STUDIES
The formulated tablets were evaluated for the following physicochemical
parameters.
1. WEIGHT VARIATION TEST:
Twenty  tablets  were  randomly  selected  from  each  batch  and
individually  weighed.  The  average  weight  and  standard  deviation  of  20
tablets was calculated. The batch passes the test for weight variation test if
not more than two of the individual tablet weight deviates from the average
weight by more than the percentage shown in table no.18, and none deviate
by more than twice the percentage shown.
Table No.18
Weight variation tolerance for Tablet (USP)
S.No
Percentage Deviation allowed under Weight
Variation test.
Average weight of
tablet X mg
Percentage deviation.
1 X < 130 mg 10
2 130 < X < 324 mg 7.5
3 X < 324 mg 5
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2. HARDNESS OF TABLET:
Hardness of the tablets was determined by using Digital Hardness Tester.
Twenty tablets from each batch were randomly selected. The force required
to break the tablet is recorded. The unit is Newton. The hardness of IP limits
is NLT 5-8 kg/cm2.
The mean of measured hardness of tablets of each batch are shown in table
no:19
3. FRIABILITY OF TABLET:
Friability of  the tablets  was  tested using a  Friabilator  (Friability
testing  apparatus,  Electro  lab).  A  loss  of  less  than  1&  in  weight  was
acceptable. The weight of 10 tablets was noted initially (W1) and placed in
the friabilitor for 4 minutes/25 rpm. (Revolution per minutes). The tablets
were reweighed and noted as (W2).
The difference in the weight is noted and expressed as percentage.
 (W1 – W2) 
            Percentage friability (%F) =      ------------------------×100
                                                                    W1
Where,
                 %F = Friability in percentage.
                 W1 = Initial weight of tablet.
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                 W2 = Weight of tablets after revolution.
The mean of measured friability of tablets of each batch are shown in table
no: 19
4. DRUG CONTENT: Five tablets of each formulation were weighed and
powdered. The quantity of powder was equivalent weight of Gabapentin was
transferred  into  100ml  volumetric  flask  and  by  using  methanol  as  the
extracting  solvent  and  the  samples  was  analyzed  by
spectrophotometrically.The results are listed in table no.19
Table No.19
PHYSICAL PARAMETERS OF GABAPENTIN TABLETS
B. No.
Average
Weight
(mg)
Hardness
(kg)
Friability
(%)
Percentage
drug
content
(%)
F1 321±1.35 5.2±0.02 0.840 99.50
F2 323±1.82 5.1±0.03 0.812 100.3
F3 329±2.45 5.5±0.04 0.840 100.1
F4 334±3.75 5.7±0.02 0.831 99.8
F5 324±1.62 5.2±0.05 0.811 99.65
F6 325±2.53 5.5±0.03 0.652 99.95
F7 328±2.75 5.6±0.02 0.725 100.4
F8 336±2.98 5.1±0.04 0.845 100.1
F9 327±1.28 5.2±0.03 0.832 100.2
F10 329±1.55 5.4±0.01 0.840 99.9
F11 333±2.78 5.2±0.03 0.821 99.89
F12 335±2.04 5.5±0.02 0.832 100.1
F13 328±2.82 5.2±0.05 0.795 100.2
F14 332±2.53 5.3±0.03 0.823 100.2
F15 334±2.73 5.4±0.04 0.822 99.98
F16 337±3.04 5.7±0.01 0.755 99.95
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5. IN VITRO DISSOLUTION STUDIES OF TABLETS
Dissolution parameters:
• Apparatus – USP-II.
• Dissolution medium – 0-2hrs (0.1HCl)
3-12hrs (6.8 phosphate buffer)
• RPM-----50.
• Sampling Interval-----1,2,3,4,5,6,7,8,9,10,11,12hrs.
• Temperature---------37 ±0.5ºc.
Dissolution study:
As the preparation was for prolonged release given through oral  route of
administration,  different  receptor  fluids  are  used  for  evaluation  of  the
dissolution profile.
Procedure: 900ml of 0.1HCl solution was placed in the vessel and the USP
—II apparatus (paddle Method) was assembled. The medium was allowed to
equilibrate to temperature of 37±0.5ºc.The tablets of each batch were placed
in the vessels and the vessels are covered. The apparatus was operated for
2hrs  and  the  medium Phosphate  buffer  6.8  was  taken  for  the  continued
process from 3-12hrs at 50 rpm. At a definite time intervals of 5ml of the
receptor  fluid  was  withdrawn,  filtered  again  5ml  of  receptor  fluid  was
replaced.  Suitable  dilutions  were  done  with  receptor  fluid  and  analyzed
spectrophotometrically at 270nm using U.V-Spectrophotometer.
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6.  DRUG RELEASE  KINETICS  -  MODEL  FITTING  OF  THE
DISSOLUTION DATA DRUG RELEASE KINETICS
Whenever a new solid dosage form is developed or produced, it  is
necessary to ensure that drug dissolution occurs in an appropriate manner.
Drug dissolution from solid  dosage forms has  been  described  by kinetic
models in which the dissolved amount of drug (Q) is a function of the test
time,  t or  Q=f (t).  Some  analytical  definitions  of  the  Q (t)  function are
commonly  used,  such  as  Zero  order,  First  order,  and  Higuchi  and
Korsmeyer–Peppas models.
Table No.20
DRUG RELEASE KINETICS
Kinetic
Model Relation
Systems Following the
Model
First order ln Qt = ln Qo + Kt
(release is proportional to amount of
drug remaining)
Water-soluble drugs in
porous matrix
Zero order ft = Kot
(independent of drug concentration)
Transdermal systems
Osmotic systems
Higuchi ft=KHt1/2
(proportional to square root of time)
Matrix formulations
Peppas –
Korsemeyer
Mt  / Mα =
Kst2
Erodible isometric matrices
ft = Fraction of dose 
released at time‘t’;
KH, Ko, and Ks = release
rate constants 
characteristic to 
respective models; 
Qo = The drug amount 
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remaining to be 
released at zero hour;
Qt = The drug amount 
remaining to be 
released at time ‘t’;
 Mt = Initial amount of 
drug present in the 
matrix at time‘t’, 
 Mα = Amount of drug 
released at time ‘α’.
7. MECHANISMS OF DRUG RELEASE
To find out the drug release mechanism due to swelling (upon hydration)
along with gradual erosion of the matrix, first 60% drug release data can be fitted
in  Korsmeyer–Peppas  model  which  is  often  used  to  describe  the  drug  release
behaviour from polymeric  systems  when the  mechanism is  not  well-known or
when more than one type of release phenomena is involved.
                                       Log (Mt / M∞) = Log KKP + n Log t
     Where,
                    Mt is the amount of drug release at time t,
                    M∞ is the amount of drug release after infinite time;
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KKP is  a  release  rate  constant  incorporating  structural  and  geometrical
characteristics of the tablet, and n is the release exponent indicative of the
mechanism of drug release.
Table No.21
Diffusion Exponent and Solute Release Mechanism for Cylindrical Shape
TABLE NO.22
COEFFICIENT CORRELATION (R) VALUES FROM IN VITRO DISSOLUTION
RATES OF GABAPENTIN TABLETS
Batch
N0. Zero Order First Order Higuchi’s Peppas’s
F1 0.98740 0.9630 0.9848 0.9367
F2 0.9907 0.9601 0.9822 0.9211
F3 0.9944 0.9889 0.9769 0.9301
F4 0.9957 0.9901 0.9751 0.9342
F5 0.9943 0.9829 0.9788 0.9380
F6 0.9959 0.9830 0.9736 0.9369
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Diffusion exponent
(n)
Overall solute diffusion
mechanism
0.45 Fickian diffusion
0.45 < n < 0.89 Anomalous (non-Fickian)diffusion
0.89 Case-II transport
n > 0.89 Super case-II transport
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F7 0.9618 0.9838 0.9690 0.9336
F8 0.9975 0.9909 0.9668 0.9801
F9 0.9890 0.9902 0.9851 0.9348
F10 0.9925 0.9913 0.9828 0.9345
F11 0.9940 0.9934 0.9798 0.9349
F12 0.9970 0.9824 0.9748 0.9318
F13 0.9942 0.9886 0.9796 0.9324
F14 0.9955 0.9792 0.9786 0.9320
F15 0.9967 0.9734 0.9721 0.9332
F16 0.9975 0.9701 0.9648 0.9341
TABLE NO.23
DISSOLUTION PROFILE OF GABAPENTIN TABLETS PREPARED WITH CALCIUM
CARBONATE IN DIFFERENT CONCENTRATIONS [F1, F2, F3, and F4]. F-WITHOUT
ANY ELECTROLYTES.
TIME
(hrs)
 CUMULATIVE PERCENTAGE  DRUG RELEASE     
F F1 F2 F3 F4
1. 36.07 21.20 19.27 16.20 15.78
2. 53.95 34.25 32.07 28.23 25.19
3. 66.32 42.06 37.47 34.11 32.08
4. 81.59 47.05 45.61 42.43 40.11
5. 90.95 53.96 50.23 46.89 45.24
6. 98.92 61.38 59.80 56.99 55.26
7. 101.50 67.30 66.15 63.62 60.22
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8. 97.54 70.84 68.94 66.06 64.62
9. 96.14 80.04 78.74 76.33 74.61
10. 95.88 89.31 87.99 85.14 83.76
11. 93.17 90.28 91.21 93.17 90.79
12. 90.79 95.57 92.37 96.26 93.04
Figure No.5
Dissolution profile of Gabapentin with Calcium Carbonate.
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TABLE NO.24
DISSOLUTION PROFILE OF GABAPENTIN TABLETS PREPARED
WITH MAGNESIUM CARBONATE IN DIFFERENT CONCENTRATIONS
[F5, F6, F7, F8].F-WITHOUT ANY ELECTROLYTES.
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Dissolution profile of Gabapentin with Magnesium Carbonate.
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TIME
(hrs)
CUMULATIVE PERCENTAGE DRUG RELEASE
F F5 F6 F7 F8
1. 36.07 17.36 14.35 11.11 09.63
2. 53.95 25.58 23.10 22.32 20.10
3. 66.32 35.74 32.99 29.39 27.09
4. 81.59 41.23 38.26 36.99 33.25
5. 90.95 46.93 44.28 42.07 40.58
6. 98.92 53.64 52.92 50.45 48.50
7. 101.50 60.39 58.33 56.38 54.36
8. 97.54 66.35 63.28 62.04 60.11
9. 96.14 73.58 70.87 69.54 68.75
10. 95.88 81.56 79.94 78.56 73.56
11. 93.17 89.12 88.01 86.25 82.69
12. 90.79 92.65 93.27 95.05 94.12
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                                           TABLE NO.25
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DISSOLUTION PROFILE OF GABAPENTIN TABLETS PREPARED
WITH SODIUM BICARBONATE IN DIFFERENT CONCENTRATIONS
[F9, F10, F11, F12].F-WITHOUT ANY ELECTROLYTES.
Dissolution profile of Gabapentin with Sodium Bicarbonate.
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TIME
(hrs)
 CUMULATIVE PERCENTAGE DRUG RELEASE 
F F9 F10 F11 F12
1. 36.07 24.15 22.65 20.45 17.35
2. 53.95 29.27 28.15 26.18 24.00
3. 66.32 39.67 37.69 35.08 31.65
4. 81.59 47.72 45.92 43.66 39.65
5. 90.95 55.36 51.58 48.36 46.28
6. 98.92 59.65 58.73 56.92 53.79
7. 101.50 69.35 66.81 64.36 61.59
8. 97.54 71.12 72.41 70.63 69.17
9. 96.14 79.61 78.74 75.68 75.50
10. 95.88 88.07 87.20 85.40 82.36
11. 93.17 92.49 94.63 93.55 92.57
12. 90.79 94.68 96.73 95.36 96.15
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TABLE NO.26
DISSOLUTION PROFILE OF GABAPENTIN TABLETS PREPARED
WITH SODIUM CARBONATE IN DIFFERENT CONCENTRATIONS [f13,
f14, f15, f16].f-WITHOUT ANY ELECTROLYTES
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Figure No.8
Dissolution profile of Gabapentin with Sodium Carbonate.
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TIME
(hrs)
CUMULATIVE PERCENTAGE DRUG RELEASE
F F13 F14 F15 F16
1. 36.07 19.64 18.54 17.98 16.15
2. 53.95 26.18 25.24 23.08 20.78
3. 66.32 35.45 34.14 31.99 29.24
4. 81.59 42.70 41.75 37.40 35.36
5. 90.95 51.32 48.96 44.74 41.81
6. 98.92 58.36 55.93 53.42 51.11
7. 101.50 63.28 62.30 60.42 57.84
8. 97.54 68.02 67.12 65.08 61.85
9. 96.14 78.36 77.54 72.74 70.87
10. 95.88 88.36 84.01 82.74 81.36
11. 93.17 93.29 92.25 90.43 89.12
12. 90.79 95.03 100.53 94.45 96.43
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11. STABILITY STUDIES OF THE OPTIMIZED BATCH
                              Stability of a formulation can be defined as the time from date
on manufacture of the formulation until its chemical or biological activity is not
less than a predetermined level of labeled potency and its physical characteristics
have not changed appreciably or deleteriously.
                            Formulation and the development of a pharmaceutical product is
not  complete  without  proper  stability  analysis,  carried  out  on  it  to  assess  the
physical and chemical stability and the safety. The purpose of stability testing is to
provide evidence on how the quality of a drug substance varies with time. Under
the influence of a variety of environmental factors such as temperature, humidity
and light, enabling recommended storage conditions, re-test periods and shelf lives.
                          Generally, the observation of the rate at which the product
degrades  under  normal  room  temperature  requires  a  long  time.  To  avoid  the
undesirable delay, the principles of accelerated stability studies are adopted.
                          The International Conference on Harmonization (ICH) Guidelines
titled stability testing of new drug substances and product describes the stability
test requirements for drug registration application in the European Union, Japan
and  United  states  of  America.  ICH  specifies  the  length  of  study  and  storage
conditions.
  Long term testing   :    25 ˚C ± 2 ˚ C and 60 % ± 5 % RH for 24 months.
 Accelerated testing:    40 ˚ C ± 2 ˚ C and 75 % ± 5 % RH for 6 months.
Stability studies work for present work carried out at controlled room temperature.
i.e. Long term studies at 25 ˚C ± 2 ˚ C and 60 % ± 5 % RH for 3 months. 
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For  any  Extended  or  Controlled  release  formulations  containing  the  water
swellable polymers like HPMC, at high temperatures de-Polymerization take place.
So their stability studies will carry out at long term studies.
Method: 
             The selected blister packed formulations stored at 25˚C ± 2 ˚ C and 60 % ±
5 % RH for 12 weeks and evaluated for their physical appearance and drug content
at specified intervals of time. The formulations were further scanned to observe
any possible spectral changes and also performed in-vitro dissolution studies. The
results are tabulated in table no.27
TABLE NO.27
STABILITY DATAS
Padmavathi College of Pharmacy & Research Institute, Dharmapuri. Page 91 
Specification
(Limits) Initial 1 Month 2 Months
Description Complies Complies Complies
Average
Weight
(330 ± 10 mg)
332 334 334
Hardness
NLT
(5.0K.g/cm2)
5.3 5.4 5.2
Dissolution of
Best Batch
(F14)
1st  --    18.94
6th   --    55.34
12th --    100.53
1st --   17.41
6th  --  54.12
12th --  99.72
1st --  17.12
6th --   52.11
12th --  98.14
Assay
(99.9- 100.9 %) 100.2 99.96 99.93
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12. RESULTS AND DISCUSSION
                      The present study was under taken to evaluate and to design the
controlled  release  matrix  tablet  of  Gabapentin  with  HPMC  by  employing
electrolytes  as  rate  retardants.  All  the  batches  were  evaluated  for  physical
parameters and also for the in vitro evaluation studies.
                      The results show various dissolution parameters computed for all the
controlled  release  formulations.  The  total  Gabapentin  drug  release  was  about
100.57% indicating almost the complete drug release from the formulation of F14
with the electrolyte as sodium carbonate.
                      The inclusion of the electrolyte with in the swollen matrix for
controlling the release rate of Gabapentin might lead to the formulation of free
base of drug and fundamental structure change in gel boundary, thus indicating the
textual variation in swollen matrix. The mechanism may prevail during the period
of drug release from the swollen gel structure. As the dissolution medium enters
the tablet, there is a rapid electrolyte water interaction with significant chemical
reaction. From these changes and alterations the mechanism of intragel is possible
to inhibit the drug release rate.
                      The stability studies were performed on selected formulation i.e., F14
at  25±2˚C  and  60±5%RH  at  the  interval  of  2  months  .The  formulation  were
checked for physical  appearance,  drug content,  hardness and dissolution. There
was no physical change has been observed in the  formulation at all and also there
was  no  significant  change  has  been  observed  in  drug  content,  hardness  and
dissolution  of  the  selected  formulation  and  the  specific  conditions.  So  F14
formulation were found to be stable.
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13. CONCLUSION
                          From the above results and discussion it was  concluded that
electrolytes can be used as aids to controlled drug delivery in the formulation of
water soluble drugs from the tablet matrix.
The release rate of drug from the matrix tablets can be
governed by the polymer and concentration of the electrolytes  employed in the
preparation of tablets.
                         The electrolyte of sodium carbonate was more effective release rate
retardants than the other electrolytes. The optimal batch formulation F14 which
showed  an  optimal  release  pattern  up  to  12hrs.  The  batch  formulation  F14  of
sodium carbonate at an optimal concentration is effective and can be administered
twice daily.
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